journal article·2026-11

Systematic engineering of Layer-by-Layer anti-miR coated wound dressings with tunable release kinetics

Adam G. Berger, Chau Vo, Justin A. Kaskow, Shruti Rawal, Eva Cai, Elad Deiss-Yehiely, Namita Nabar, Tamara G. Dacoba, Michael Marand, Joon Ho Park, Gil Covarrubias, Charles DeLorenzo, Mark W. Feinberg, Paula T. Hammond

Publisher page

Abstract

The Layer-by-Layer (LbL) technique enables conformal coating of commercial wound dressings with oligonucleotide therapeutics and polymeric excipients to achieve controlled delivery to non-healing wounds. We previously demonstrated a proof-of-concept LbL dressing containing miRNA inhibitors (anti-miRs); however, release occurred on a single time scale. Because wound healing is dynamic, temporally tuning anti-miR delivery to the wound may alter therapeutic effects. Here, we provide an approach to modulate oligonucleotide release kinetics from coated wound dressings, exploring the design space of excipients, formulation parameters, and oligonucleotide structure. Incorporation of Laponite nanoclay prolonged release, while poly(acrylic acid) accelerated release kinetics. Hydrolyzable poly(β-amino esters) with varying hydrolysis rates were also used to further tune release kinetics. A fast-release formulation demonstrated 40% release over 4 h, while a slow-release formulation took 24 h to release the same amount. We evaluated these dressings in an excisional chronic wound model in diabetic (db/db) mice using anti-miR-92a (92ai), selected for its ability to enhance angiogenic signaling and promote wound closure. Dressings coated with 92ai accelerated healing compared to non-targeting scramble anti-miR (Scr) controls, with closure rates accelerated at times corresponding to release kinetics. Although ultimate wound closure was similar across release conditions, analyses of gene expression, cellular composition, histology, and immunofluorescence suggested distinct underlying mechanisms. Differences were particularly evident in macrophage phenotype and angiogenesis, suggesting that release timing influences biological pathways active during repair. Overall, these findings demonstrate that LbL dressings can be engineered for temporally controlled oligonucleotide delivery and that release kinetics may shape mechanisms driving wound closure.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Wound Healing and Treatments · Polymer Surface Interaction Studies · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (75)

Show source-provided references
1. Diabetic foot ulcers and their recurrence10.1056/NEJMra1615439 ↗
2. Diabetic foot ulcers: a review10.1001/jama.2023.10578 ↗
3. Health-related quality of life in diabetic patients with foot ulcers: literature review10.1097/00152192-200511000-00007 ↗
4. An economic evaluation of the impact, cost, and Medicare policy implications of chronic nonhealing wounds10.1016/j.jval.2017.07.007 ↗
5. miRNA delivery for skin wound healing10.1016/j.addr.2017.12.011 ↗
6. MicroRNAs in diabetic wound healing: pathophysiology and therapeutic opportunities10.1016/j.tcm.2018.08.002 ↗
7. MicroRNA as therapeutic targets for chronic wound healing10.1016/j.omtn.2017.06.003 ↗
8. Approaches to modulate the chronic wound environment using localized nucleic acid delivery10.1089/wound.2020.1167 ↗
9. Layer-by-layer biomaterials for drug delivery10.1146/annurev-bioeng-060418-052350 ↗
10. A design approach for layer-by-layer surface-mediated siRNA delivery10.1016/j.actbio.2021.08.042 ↗
11. Nanolayered siRNA dressing for sustained localized knockdown10.1021/nn401011n ↗
12. Self-assembled wound dressings silence MMP-9 and improve diabetic wound healing in vivo10.1002/adma.201503565 ↗
13. Nanolayered siRNA delivery platforms for local silencing of CTGF reduce cutaneous scar contraction in third-degree burns10.1016/j.biomaterials.2016.04.007 ↗
14. Electrostatically assembled wound dressings deliver pro-Angiogenic anti-miRs preferentially to endothelial cells10.1016/j.biomaterials.2023.122188 ↗
15. Acceleration of diabetic wound healing with PHD2- and miR-210-targeting oligonucleotides
16. Use of therapeutic RNAs to accelerate wound healing in diabetic rabbit wounds10.1089/wound.2023.0056 ↗
17. MicroRNAs: genomics, biogenesis, mechanism, and function10.1016/S0092-8674(04)00045-5 ↗
18. Wound repair and regeneration: mechanisms, signaling, and translation10.1126/scitranslmed.3009337 ↗
19. Inhibition of microRNA with antisense oligonucleotides10.1016/j.ymeth.2007.11.001 ↗
20. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting10.1016/j.cmet.2006.01.005 ↗
21. Assembly of bifunctional aptamer–fibrinogen macromer for VEGF delivery and skin wound healing10.1021/acs.chemmater.8b04486 ↗
22. Poly(β-aminoester) physicochemical properties govern delivery of siRNA from electrostatically assembled wound dressings10.1021/acs.biomac.4c00062 ↗
23. Combination growth factor therapy via electrostatically assembled wound dressings improves diabetic ulcer healing in vivo10.1002/adhm.201500403 ↗
24. Catechol-modified polyions in layer-by-layer assembly to enhance stability and sustain release of biomolecules: a bioinspired approach10.1021/cm201801n ↗
25. Graphene multilayers as gates for multi-week sequential release of proteins from surfaces10.1021/nn202607r ↗
26. Laponite®: a key nanoplatform for biomedical applications?10.1016/j.nano.2017.04.016 ↗
27. Laponite-based nanomaterials for drug delivery10.1002/adhm.202102054 ↗
28. Tunable staged release of therapeutics from layer-by-layer coatings with clay interlayer barrier10.1016/j.biomaterials.2013.12.009 ↗
29. Sustained release of BMP-2 using self-assembled layer-by-layer film-coated implants enhances bone regeneration over burst release10.1016/j.biomaterials.2022.121721 ↗
30. Mathematical models of drug release
31. Balancing cationic and hydrophobic content of PEGylated siRNA Polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo10.1021/nn403325f ↗
32. Quantitative and reproducible murine model of excisional wound healing10.1111/j.1067-1927.2004.12404.x ↗
33. MicroRNA-135a-3p regulates angiogenesis and tissue repair by targeting P38 signaling in endothelial cells10.1096/fj.201802063RR ↗
34. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a10.1016/j.yjmcc.2016.01.007 ↗
35. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – excel-based tool using pair-wise correlations10.1023/B:BILE.0000019559.84305.47 ↗
36. Flow cytometry analysis of the subpopulations of mouse keratinocytes and skin immune cells10.1016/j.xpro.2021.101052 ↗
37. Molecular basis for the explanation of the exponential growth of polyelectrolyte multilayers10.1073/pnas.202486099 ↗
38. Comparison of the structure of polyelectrolyte multilayer films exhibiting a linear and an exponential growth regime: an in situ atomic force microscopy study10.1021/ma0119833 ↗
39. Exponential growth of LBL films with incorporated inorganic sheets10.1021/nl8011648 ↗
40. Composite biomaterials of polyelectrolyte complex micelle nanoparticles in hyaluronic acid gels enable local, targeted miR-92a inhibition and enhanced angiogenesis in diabetic wound repair10.1016/j.jconrel.2026.115031 ↗
41. A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds10.1111/wrr.12660 ↗
42. Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice10.1038/ncomms15162 ↗
43. Biochemical analysis of wound fluid from nonhealing and healing chronic leg ulcers10.1046/j.1524-475X.1996.40211.x ↗
44. Simple biochemical markers to assess chronic wounds10.1046/j.1524-475x.2000.00264.x ↗
45. Berger · 2024
46. Inhibition of miR-92a improves re-Endothelialization and prevents Neointima formation following vascular injury10.1093/cvr/cvu162 ↗
47. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model10.1161/CIRCULATIONAHA.113.001904 ↗
48. Analysis of cell type-specific effects of MicroRNA-92a provides novel insights into target regulation and mechanism of action10.1161/CIRCULATIONAHA.118.034598 ↗
49. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice10.1126/science.1174381 ↗
50. Extracellular microRNA-92a mediates endothelial cell-macrophage communication10.1161/ATVBAHA.119.312707 ↗
51. Inflammation and wound healing: the role of the macrophage10.1017/S1462399411001943 ↗
52. Macrophage polarization and diabetic wound healing10.1016/j.trsl.2021.05.006 ↗
53. A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers10.1126/scitranslmed.aaf8611 ↗
54. Single cell transcriptomic landscape of diabetic foot ulcers10.1038/s41467-021-27801-8 ↗
55. Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing10.1038/s41467-020-18276-0 ↗
56. Topical application of a mast cell stabilizer improves impaired diabetic wound healing10.1016/j.jid.2019.08.449 ↗
57. Spatial expression of Metallothionein, matrix Metalloproteinase-1 and Ki-67 in human epidermal wounds treated with zinc and determined by quantitative immunohistochemistry: a randomised double-blind trial10.1016/j.ejcb.2020.151147 ↗
58. Central roles of Α5β1 integrin and fibronectin in vascular development in mouse embryos and Embryoid bodies10.1161/01.ATV.0000016045.93313.F2 ↗
59. Protective effects of macrophage-specific integrin Α5 in myocardial infarction are associated with accentuated angiogenesis10.1038/s41467-023-43369-x ↗
60. Alpha-smooth muscle actin is transiently expressed by Myofibroblasts during experimental wound healing
61. The myofibroblast, a key cell in normal and pathological tissue repair10.1007/s00018-015-2110-0 ↗
62. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments10.1373/clinchem.2008.112797 ↗
63. Metalloproteinases and wound healing10.1089/wound.2014.0581 ↗
64. Acceleration of diabetic wound healing using a novel protease–anti-protease combination therapy10.1073/pnas.1517847112 ↗
65. MMP-13 plays a role in keratinocyte migration, angiogenesis, and contraction in mouse skin wound healing10.2353/ajpath.2009.081080 ↗
66. Hypoxia induces epidermal keratinocyte matrix Metalloproteinase-9 secretion via the protein kinase C pathway10.1002/jcp.21160 ↗
67. Complex role of matrix metalloproteinases in angiogenesis10.1038/cr.1998.17 ↗
68. Role of matrix metalloproteinases in angiogenesis and cancer10.3389/fonc.2019.01370 ↗
69. Integrated skin transcriptomics and serum multiplex assays reveal novel mechanisms of wound healing in diabetic foot ulcers10.2337/db20-0188 ↗
70. Diabetic wound regeneration using heparin-mimetic peptide Amphiphile gel in Db/Db mice10.1039/C7BM00251C ↗
71. Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse10.2337/diabetes.53.9.2509 ↗
72. Db/Db mice exhibit severe wound-healing impairments compared with other murine diabetic strains in a silicone-splinted excisional wound model10.1111/j.1524-475X.2007.00273.x ↗
73. Full-thickness splinted skin wound healing models in Db/Db and heterozygous mice: implications for wound healing impairment10.1111/wrr.12172 ↗
74. Reactive oxygen species–degradable polythioketal urethane foam dressings to promote porcine skin wound repair10.1126/scitranslmed.abm6586 ↗
75. A strain-programmed patch for the healing of diabetic wounds10.1038/s41551-022-00905-2 ↗